Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 7:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,666 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
92
States / cities
Birmingham, Alabama • Goodyear, Arizona • Concord, California + 81 more
Conditions
Type 1 Diabetes
Interventions
Transition Social Behavioral Intervention, Diabetes Transition Clinic
Behavioral
Lead sponsor
University of Kansas
Other
Eligibility
16 Years to 29 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Completed Phase 1 Interventional Results available

OPT101 in Type 1 Diabetes Patients

NCT05428943
Conditions
Diabetes Mellitus, Type 1
Interventions
OPT101
Drug
Lead sponsor
Op-T LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Walnut Creek, California • Renton, Washington
Conditions
Type 1 Diabetes Mellitus
Interventions
PolyTregs+IL-2
Biological
Lead sponsor
Jeffrey Bluestone
Other
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
San Francisco, California • New Haven, Connecticut
Conditions
Type 1 Diabetes Mellitus
Interventions
AID System, Insulin Lispro
Device · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Renton, Washington
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

NCT00308308
Conditions
Diabetes, Type I
Interventions
Technosphere Insulin, Active comparator
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
589 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
61
States / cities
Mobile, Alabama • Chandler, Arizona • Chula Vista, California + 48 more
Conditions
Type 1 Diabetes, Pregnancy
Interventions
Frequent remote contact between clinic visits.
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 3 Interventional Results available

Adjunctive Metformin Therapy in Double Diabetes

NCT01334125
Conditions
Diabetes Mellitus
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
10 Years to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
INGAP Peptide
Drug
Lead sponsor
GMP Endotherapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
4
States / cities
San Diego, California • Washington D.C., District of Columbia • Durham, North Carolina + 1 more
Completed Phase 2 Interventional Results available

Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes

NCT00378508
Conditions
Type 1 Diabetes Mellitus
Interventions
mAb hOKT3gamma1(Ala-Ala), Teplizumab, Placebo Arm
Drug
Lead sponsor
Yale University
Other
Eligibility
8 Years to 30 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
4
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 1 more
Conditions
Type 1 Diabetes, Eating Disorders, Disordered Eating Behaviors, Purging (Eating Disorders), Binge-Eating Disorder
Interventions
ACT, Supportive Diabetes Counseling
Behavioral
Lead sponsor
Duke University
Other
Eligibility
16 Years to 50 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Durham, North Carolina • Providence, Rhode Island
Conditions
Type 1 Diabetes (T1D), Sleep Health
Interventions
Sleep Health and Circadian Timing Intervention
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
14 Years to 19 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Diabetes
Interventions
BD Continuous glucose monitor (BD CGM), YSI Glucose Analyzer, Medtronic Guardian CGM
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Type 1 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo for dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
36
States / cities
Little Rock, Arkansas • Encino, California • La Mesa, California + 33 more
Terminated Not applicable Interventional Results available

Continuous Glucose Monitoring Initiation at Hospital Discharge

NCT04854135
Conditions
Type 1 Diabetes, Type2 Diabetes, Hyperglycemia, Hypoglycemia, Hypoglycemia Unawareness
Interventions
CGM4Home
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Glimepiride
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Diabetes Mellitus, Type 1, Diabetes, Diabetes, Autoimmune
Interventions
ILT-101 (Aldesleukin; IL-2), Treatment-Placebo Arm, Placebo Arm
Biological · Other
Lead sponsor
Jay S. Skyler
Other
Eligibility
8 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Conditions
Type 1 Diabetes
Interventions
ePID closed loop system, InsuPatch
Device
Lead sponsor
Yale University
Other
Eligibility
12 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Diabetes Mellitus Type 2, Diabetes Mellitus, Type 1, Primary Care Provider
Interventions
The Diabetes Treatment Satisfaction Questionnaire, Diabetes Empowerment Scale, CBOC's undergo half-day joint-clinics via teleconference
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cleveland, Ohio
Terminated Phase 1Phase 2 Interventional Results available

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

NCT00672204
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia
Interventions
Allogeneic islets of Langerhans transplant, Raptiva, Sirolimus, anti-thymocyte globulin
Biological · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed No phase listed Observational Accepts healthy volunteers

Genetic Influence on Susceptibility to Type 1 Diabetes Mellitus

NCT00001985
Conditions
Diabetes Mellitus, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogeneic Cultured Islet Cells (human); Encapsulated
Biological
Lead sponsor
Novocell
Industry
Eligibility
20 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
San Antonio, Texas
Conditions
Type 1 Diabetes Mellitus
Interventions
Afrezza
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
4 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 8 more
Conditions
Type 1 Diabetes
Interventions
Artificial Pancreas (AP)
Device
Lead sponsor
University of Virginia
Other
Eligibility
11 Years to 12 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia